BroadcomAVGO
$1.70T market capClassified by the SEC under semiconductors and related devices.
Broadcom in 28 checks
Broadcom at a glance: how it scores on value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
Strong business, priced for a lot of it - 15 of 28 checks passed.
Value
What you pay today for what the business produces, measured against AVGO's own history and its peers, never a universal rule.
Expensive against its own history and its sector - you're paying up for what you get.
Is the price high or low right now, compared to what the market usually pays?
→At 52.2x earnings, the market is paying +96% more than AVGO's own 4-year median of 26.6x. Expectations are elevated, so more has to go right to justify the price. Today's multiple is the highest in the charted history.
What has the market paid for AVGO over the years?
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 52.2x earnings, the market is paying +96% more than AVGO's own 4-year median of 26.6x. Expectations are elevated, so more has to go right to justify the price. Today's multiple is the highest in the charted history.
What cash return does the business throw off per dollar of market value?
1.9%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 1.9%, you get less cash per dollar of market value than the 5-year median of 7.4% - the market is charging more for the same cash.
What does “Value” actually mean?
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
How we scored it · 0 of 5 checks passed
| ✕ | Cheaper than its own history (earnings) | 52.15 vs 26.58 |
| ✕ | Earnings yield beats a long bond (4%) | 1.9% vs 4.0% |
| ✕ | Better cash yield than its own history | 1.9% vs 7.4% |
| ✕ | Free cash flow yield above 3% | 1.9% vs 3.0% |
| ✕ | Cheap on enterprise value | 52.42 vs 14.00 (peer median) |
| – | Price isn't outrunning growth | no positive 3-year earnings growth to compare against |
Growth
What the company has actually reported - is it selling more, and is more of it becoming profit?
Not enough data to score this fairly - the checks below show exactly what's missing.
Revenue: is the business selling more than it used to?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $35.8B in 2023, compounding +13% a year since 2017 and the pace is picking up. The trailing twelve months are already running at $75.5B, ahead of the last full year.
Net income: how much of that revenue becomes profit?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $14.1B in 2023, compounding +42% a year over three years. Trailing twelve-month profit stands at $29.3B.
How fast is it growing, year by year?
+8%revenue growth, FY 2023
Shown separately because they would flatten the axis: 2021 earnings +298% - rebounds off a collapsed prior year.
→In 2023 revenue grew +8% while earnings moved +23% - when the earnings line runs above revenue, each new dollar of sales is arriving more profitably.
What does “Growth” actually mean?
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
How we scored it · 0 of 0 checks passed
| – | Outgrew its sector last year | under 8 quarters of history |
| – | Sustained growth beats its sector (3 years) | under 3 years of history |
| – | Profits grew last year | loss-making in both years |
| – | Profit growth beats its peers | earnings at or below zero at either end |
| – | Growth is speeding up, not slowing | under 3 years of history |
| – | Grew per share, not just in total | under 3 years of per-share history |
Quality
Whether the growth makes real money - margins, returns on capital, and whether profits turn into cash.
Rare profitability: margins and returns on capital are well above its peers.
Margins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-05-03), not a full fiscal year
→Operating margin widened 14 points to 45% since 2021. After everything, 39 cents of each sales dollar reaches net profit.
Earnings quality: do the reported profits turn into real cash?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-05-03), not a full fiscal year
→Operating cash flow tracks reported profit almost exactly (115%). The earnings are real cash, not accounting.
What does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-05-03), not a full fiscal year
→ROE of 20% but ROCE of only 10% - a chunk of those shareholder returns is manufactured with leverage, not operations.
Where does each dollar of revenue actually go?
→Of $35.8B in sales, $24.7B survives production costs, $16.2B survives running the company, and $14.1B - 39¢ of every dollar - reaches the bottom line.
How much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→49 cents of every sales dollar became free cash in 2023, and it has held steady since 2021 - the best conversion in its filed history.
What does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-05-03), not a full fiscal year
→The biggest claim on each sales dollar is research and development, at 15% of revenue (stock compensation 6%, capital spending 1%). That share has fallen since 2017, so the cost of competing is easing.
Does AVGO earn more on its capital than that capital costs?
→AVGO earns 10.3% on the capital it employs, comfortably above the 10% most investors treat as the cost of capital. It was 4.6% in 2017, so the trend is up, and the pace is picking up.
What does “Quality” actually mean?
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
How we scored it · 6 of 6 checks passed
| ✓ | Better gross margins than peers | 68.3% vs 44.7% (sector 70th pct, n=155) |
| ✓ | Runs leaner than peers (operating margin) | 43.4% vs 8.5% (sector 70th pct, n=161) |
| ✓ | Actually profitable | TTM net income $29.3B |
| ✓ | Earns well on shareholders' money | 33.4% vs 11.6% (sector 70th pct, n=149) |
| ✓ | Earns a real return on the capital it employs | 20.4% vs 10.0% |
| ✓ | Profits are cash, not accounting | 1.15 vs 0.80 |
Health
The balance sheet stress test: could AVGO survive a bad year?
A fortress balance sheet - AVGO can survive a very bad year.
Could it handle its debt if things went wrong?
→Debt of $64.9B sits against $19.6B of cash, or 0.7x shareholders' equity. Earnings cover the interest bill 10 times over, so the debt is comfortably serviced.
Is the company's own capital growing or shrinking?
→The company's own capital grew from $70.3B in 2023 to $87.7B (+25%). The business is building book value rather than consuming it.
What does “Health” actually mean?
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
How we scored it · 6 of 6 checks passed
| ✓ | Comfortable near-term liquidity | 2.24 vs 1.50 |
| ✓ | Debt isn't dominating | 0.74 vs 1.00 |
| ✓ | Debt trending the right way | debt/equity 0.74 now vs 1.72 five years ago |
| ✓ | Earnings cover the interest | 10.41 vs 5.00 |
| ✓ | Converts sales to cash better than its sector | 44.6% vs 16.8% (sector 70th pct, n=166) |
| ✓ | Self-funding | TTM free cash flow $32.8B |
Shareholder returns
How much cash actually flows back to owners - dividends, buybacks, whether the share count truly falls, and whether what is handed back is affordable.
What comes back to owners is thin or stretched - read the checks before counting on it.
How much goes back to shareholders - and how much leaks out as stock compensation?
→$13.5B returned last year against $2.2B of stock issued to employees - the returns outweigh the dilution 6.2-to-1.
How fast is your ownership being diluted - or concentrated?
→0.9% more shares last year - your stake was diluted by that much.
Is the dividend cheque itself growing?
→Up from $0.19 to $1.79 per share over 7 years - the cheque keeps growing.
What does the payout earn you at each year's prices?
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At today's price the yield is 0.4%.
Can it actually afford the dividend?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-05-03), not a full fiscal year
→Comfortable: 54% of profits and 43% of free cash flow go out as dividends - well inside what the business generates.
AVGO has issued or retired shares - did shareholders end up better off?
Both lines start at 100 in 2016, so the gap between them is what each share gained or lost. Share counts are split-adjusted.
→AVGO issued +12% more shares from 2016 to 2023, but revenue per share still rose +143%. The dilution bought more growth than it cost existing holders.
Why compare buybacks with stock compensation?
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
How we scored it · 2 of 5 checks passed
| – | Share count isn't climbing | under 3 years of share counts |
| ✕ | Buybacks outpace the stock issued to staff | $8.4B bought back vs $8.8B of stock compensation |
| ✓ | What it hands back fits inside its cash flow | 61.7% vs 100.0% |
| ✕ | Meaningful yield to owners (dividends and buybacks) | $20.2B returned, 1.2% of market value |
| ✕ | Reliable payer, never cut | paid 5/10 years, worst year-on-year change 13.5% |
| ✓ | Dividend growing ahead of inflation | 362.5% vs 9.0% |
Trend analysis
What the market is doing about all of the above. This is price behaviour, not a fact about the business - read it as the market's current opinion, scored on six checks like every other chapter. The market is the S&P 500, measured by the SPY ETF with dividends included, over 3 months (63 trading sessions) and 12 months (252).
The market is voting against it right now - a falling trend on most measures.
How is AVGO's trend actually behaving right now?
Chart by TradingView
→AVGO is in a downtrend. The price is below the band where recent trading settled and that band is still falling, so nothing in the picture has turned yet. Both the last two weeks and the month-ago comparison point down as well, so nothing here disagrees with the downtrend. The band drawn for the coming weeks turns downward partway through, so that support is set to thin out from there.
How the trend above is worked out
The trend read comes from the daily Ichimoku picture, a standard trend indicator, translated out of its jargon. It builds a band from the midpoints of the last 9, 26 and 52 sessions' highs and lows - in effect, the range where recent trading has settled - and draws that band 26 sessions into the future. Price above the band is an uptrend, below it a downtrend, inside it no trend. Because the band is drawn forward, the support for the next few weeks is already fixed and a change of its direction can be seen coming. We also compare the last two weeks against the last month, and today's price against where it stood a month ago. None of this says anything about the business; it describes the price only, and it is not advice. Where a check says 'the S&P 500', the comparison is with the SPY ETF including dividends, on the same adjusted basis as the stock's own price: short means 3 months, 63 trading sessions; long means 12 months, 252.
How we scored it · 1 of 6 checks passed
| ✕ | In an uptrend | 357.90 vs 369.03 |
| ✓ | Trend structure is healthy | 383.66 vs 369.03 |
| ✕ | Rising over 3 months | -7.1% vs 0.0% |
| ✕ | Beating the S&P 500 over 3 months | -7.1% vs 4.7% |
| ✕ | Beating the S&P 500 over 12 months | 17.8% vs 20.0% |
| ✕ | Not in a deep hole | -25.6% from its 52-week high |
Insider activity
What the people running the company do with their own shares - reported to the SEC within two days, classified so pay-plumbing doesn't masquerade as conviction.
Are the people running it buying or selling with their own money?
→No open-market buying, and $284M of selling across 6 months. Selling alone is a weak signal - much of it is pre-scheduled - but the absence of buying tells you no insider saw the price as a bargain.
Who did what, exactly?
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-10 | Mark David Brazeal | Chief Legal & Corp Affairs Ofc | SELL | 25,000 | $10M |
| 2026-07-08 | Gayla J Delly | Director | SELL | 1,890 | $728,368 |
| 2026-07-08 | Mark David Brazeal | Chief Legal & Corp Affairs Ofc | SELL | 25,000 | $9M |
| 2026-06-29 | Justine Page | Director | SELL | 1,602 | $598,916 |
| 2026-06-25 | Mark David Brazeal | Chief Legal & Corp Affairs Ofc | SELL | 25,000 | $10M |
| 2026-06-24 | Henry Samueli | Director | SELL | 23,253 | $9M |
| 2026-06-24 | Henry Samueli | Director | SELL | 33,346 | $13M |
| 2026-06-24 | Henry Samueli | Director | SELL | 30,911 | $12M |
| 2026-06-24 | Henry Samueli | Director | SELL | 48,996 | $19M |
| 2026-06-24 | Henry Samueli | Director | SELL | 36,661 | $14M |
Why do the transaction types matter so much?
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.